Shanghai Junshi Biosciences’ TUOYI Gains Key Insurance Inclusion

Shanghai Junshi Biosciences Co., Ltd. Class H (HK:1877) has released an update.

Shanghai Junshi Biosciences Co., Ltd. announced that its product, Toripalimab Injection (TUOYI), has been included in the National Drug List for Basic Medical Insurance with four new indications, effective from January 2025. This makes TUOYI the only anti-PD-1 monoclonal antibody in the list for treating melanoma, non-small cell lung cancer, renal carcinoma, and triple-negative breast cancer in China. The inclusion in the national reimbursement list is a significant milestone for the company, highlighting its expanding international presence and acceptance in key medical markets.

For further insights into HK:1877 stock, check out TipRanks’ Stock Analysis page.